Your browser doesn't support javascript.
loading
Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
Zuco, Valentina; Pasquali, Sandro; Tortoreto, Monica; Brich, Silvia; Percio, Stefano; Dagrada, Gian Paolo; Colombo, Chiara; Sanfilippo, Roberta; Lauricella, Calogero; Gounder, Mrinal; El Bezawy, Rihan; Barisella, Marta; Dei Tos, Angelo Paolo; Casali, Paolo Giovanni; Gronchi, Alessandro; Stacchiotti, Silvia; Zaffaroni, Nadia.
Affiliation
  • Zuco V; Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori, Via Amadeo 42, 20133, Milan, Italy.
  • Pasquali S; Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori, Via Amadeo 42, 20133, Milan, Italy.
  • Tortoreto M; Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori, Via Amadeo 42, 20133, Milan, Italy.
  • Brich S; Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133, Milan, Italy.
  • Percio S; Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori, Via Amadeo 42, 20133, Milan, Italy.
  • Dagrada GP; Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133, Milan, Italy.
  • Colombo C; Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133, Milan, Italy.
  • Sanfilippo R; Adult Mesenchymal Tumor and Rare Cancer Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133, Milan, Italy.
  • Lauricella C; Molecular Pathology Unit, Ospedale Niguarda Ca' Grande, Milan, Italy.
  • Gounder M; Sarcoma Medical Oncology and Early Drug Development, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 10065, New York, NY, USA.
  • El Bezawy R; Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori, Via Amadeo 42, 20133, Milan, Italy.
  • Barisella M; Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133, Milan, Italy.
  • Dei Tos AP; Department of Medicine, University of Padua School of Medicine, Via Giustiniani 2, 35128, Padua, Italy.
  • Casali PG; Adult Mesenchymal Tumor and Rare Cancer Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133, Milan, Italy.
  • Gronchi A; Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Via Grassi 74, 20157, Milan, Italy.
  • Stacchiotti S; Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133, Milan, Italy.
  • Zaffaroni N; Adult Mesenchymal Tumor and Rare Cancer Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133, Milan, Italy.
J Exp Clin Cancer Res ; 40(1): 83, 2021 Mar 01.
Article in En | MEDLINE | ID: mdl-33648535
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Triazoles / Doxorubicin / Tumor Suppressor Protein p53 / Survivin / Hydrazines / Liposarcoma Type of study: Clinical_trials Limits: Animals / Humans / Male Language: En Journal: J Exp Clin Cancer Res Year: 2021 Type: Article Affiliation country: Italy
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Triazoles / Doxorubicin / Tumor Suppressor Protein p53 / Survivin / Hydrazines / Liposarcoma Type of study: Clinical_trials Limits: Animals / Humans / Male Language: En Journal: J Exp Clin Cancer Res Year: 2021 Type: Article Affiliation country: Italy